Publication | Closed Access

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

MedicineRandomised Phase 3ImmunologyPathologyAlectinib Versus CrizotinibBronchial NeoplasmUntreated Asian PatientsCancer TreatmentOncologyRadiation OncologyLung CancerCancer Growth